165 results
Page 2 of 9
8-K
EX-99.2
2alkamdoyd8r77u
8 Jun 23
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
4:27pm
8-K
EX-99.1
m6p 3oubpujx7k
6 Jun 23
No Vaccine Related Serious Adverse Events (SAEs) reported to date
8:07am
8-K
EX-99.1
1c3 h0awi1jmcv
9 May 23
Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results
4:57pm
8-K
EX-99.1
fn7qyy3 urspii9kv
19 Dec 22
Vaxart Names Phillip Lee as Chief Financial Officer
5:25pm
8-K
EX-99.1
qilimoh watr
6 Dec 22
Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers
4:21pm
8-K
EX-99.1
d6a4hif asmi1r0j3
8 Nov 22
Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results
4:10pm
8-K
EX-99.2
hih6f0cg
1 Sep 22
Regulation FD Disclosure
7:05am
8-K
EX-99.1
nav z2isho
1 Sep 22
Regulation FD Disclosure
7:05am
8-K
EX-99.1
7fyhfmv
25 Aug 22
Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors
4:09pm
8-K
EX-99.1
cvdqoay 8s
8 Aug 22
Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results
4:06pm
8-K/A
EX-99.1
gn5isd4gu89x
5 Aug 22
Vaxart Stockholders Approve Proxy Proposals 2, 3 and 4
8:02am
DEFA14A
ebzg121qhhr
1 Jul 22
Additional proxy soliciting materials
5:28pm
DEFA14A
ynwkbr26t vxkjs
1 Jul 22
Additional proxy soliciting materials
12:32pm
8-K
EX-99.1
6o8qdunyo01micj
16 Jun 22
Management to discuss progress on its programs, annual stockholders’ meeting proposals
4:06pm
8-K
EX-99.1
1ro 4vdt062
8 Jun 22
Vaxart Announces Adjournment of Annual Meeting of Stockholders
4:06pm
8-K
EX-99.1
9hhues q6zo19famd
9 May 22
Vaxart Provides Business Update and Reports First Quarter 2022 Financial Results
5:51pm